This reading list we received from Drs entirely disinterested. E. Valstar, (Orthomolecular) doctor / biologist. We provide this list are unchanged for publication. .
Scroll down for list.
Valstar wrote the book Nutritional intervention in cancer, a signal to the conventional oncology. See description on page, etc. ISBN cancer rates. We want to mention that we have no business or substantive ties with Engelbert Valstar, but this book and lists seem to us so interesting that we want to change places. Questions / comments can be sent to the editor: redactie@kanker-actueel.nl We will keep your questions / comments to be forwarded Valstar. Also on this list and further information on this page is of course our disclaimer applies.
More detailed descriptions and other studies see and nutrition research. And we try to at least the abstract and the results of the Phase III trials and pivotal Phase II studies in the literature list and nutrition research. or current mainstream research to publish or not fitted comments.
For regular treatments in general because the only randomized study possible side effects. Moreover, a randomized study of conventional treatments often never implemented. This assertion of Valstar based on relevant literature is in NTvG (see NTvG 136: 709-710, 1992) by the respective oncologists not contradicted.
See also Nutritional Oncology, Heber D. et al ISBN 0-12-335960-0, the book was edited by Harvard and by the Memorial Sloan Kettering Institute! ).
(Editors note: See extensive bibliography in the book of Valstar Nutritional intervention in cancer, a signal to the conventional oncology and now as published on this site)..
To this list are Hans Houtsmuller, Ed Woerlee Johan Bolhuis and important contributions.
Bibliography of studies cancer and nutrition / supplementation. Studies: 201 t / m 300
201) Zhou K et al, Zhongguo Zhong Xi Yi Jie He Za Zhi 19: 11-3, 1999; Shenqi Fuzheng improves outcome in randomized studies initial chemotherapy in gastric cancer patients significantly.
202) Yuan J et al; Hunan Yi Ke Da Xue Bao 25: 254-6, 2000, Chinese herbs reduce randomized study the effects of radiation, but have no effect on the 3 - and 5-year survival.
203) Yokoe T et al, Anticancer Res 17: 2815-8, 1997; PSK improves randomized trial in breast cancer patients, the 5 - and 10-year survival is if they possess the B40 antigen, and where they have not.
204) Morimoto T et al, Eur J Cancer 32A: 235-42, 1996, PSK improved the prognosis of women with hormone sensitive breast cancer stage 2, mitomycin and Nolvadex will not, another study mentioned earlier in this list shows that the prognosis of breast cancer at an early stage, less, or hormone insensitive, or in possession of a B40 gene, or by PSK improves.
205) Takashima S et al; Gan To Kagaku Ryoho 15: 2229-36, 1988; PSK late randomized trial in patients operated due to colon or rectal cancer, the 5-year survival was in the PSK group was not significantly (ie 11%) improved, combined analysis with the three previous trials PSK in colorectal cancer still shows a clearly better long-term survival seen with PSK, a trend analysis of this research would be interesting.
206) I. Lopez et al, Ann Internal Med (Paris) 145: 405-8, 1994, in randomized studies in patients with leukemia, vitamin E appears during induction therapy to reduce the occurrence of mucositis.
207) Deposit Hardt J et al, Arzneimittelforschung 50: 178-84, 2000; Polyerga reduces side effects in double-blind study of cisplatin / carboplatin, 5-FU in patients with inoperable throat cancer, in particular by polyerga fatigue was less.
208) Watanabe Y, Iwa T, Cancer 53: 248-53, 1984, OK-432, a streptococcal extract improves prognosis of operated lung cancer patients.
209) Fukuoka M et al; Gan To Kagaku Ryoho 11: 1543-9, 1984; Nocardia potentiates effects of adriamycin in randomized studies in lung cancer patients with pleural effusion.
210) Mitsu Takahashi K et al, Anticancer Res 13: 1815-1820, 1993; PSK improves survival of lung cancer patients treated with radiation, which covered all three stages (1,2 and3) separately.
211) HC Van Zaanen et al, Cancer 74: 2879-84; glutamine dipeptide and as part of TPN (total parenteral nutrition) is in patients with hematologic malignancies who receive chemotherapy mucositis and other side effects not against, a further analysis of the glutamine articles before taking up a more definitive conclusion.
212) Pecking AP et al, Angiology 48: 93-8, 1997; Hesperdine extract improves randomized study the lymph flow in breast cancer patients with lymphatic congestion.
213) Roszkowski K et al, Cancer Immunol Immunother 15: 23-6, 1983; Propionibacterium granulosum randomized study extends the lives of breast cancer patients with metastases who receive FAC.
214) Xie FY et al, Zhongguo Zhong Xi Yi Jie He Za Zhi 21: 332-4, 2001, ginseng polysaccharides, administered by injection improved in a randomized trial in 131 patients with nasopharynkxcarcinoom significantly the NK and LAK activity, the disease-free survival and survival were better seconds, though the effect was not significant.
215) Maehara Y et al, Am J Surg 168: 36-40, 1994, OK-432 per injection improves in a randomized trial with 36 patients operated due to gastric cancer and adjuvant chemotherapy given in addition to the survival and reduced in this study, the risk of recurrence.
216) Khuri FR et al, Cancer Epidemiol Biomarkers Prev 10: 823-9, 2001, the most active anticancer metabolite of vitamin A, 13-cis-retinoic acid in patients with throat cancer reduces both the risk of recurrence and new primary tumors.
217) Doro Show JH et al, NCI Monogr 5: 171-4, 1987, in a small randomized study showed the active form of folic acid to the action of 5-FU to improve: more regressions and longer disease-free survival.
218) Kasse Roller R, Anticancer Res 18: 2227-30, 1998; selenite reduces randomized double-blind trial lymphatic edema in breast cancer patients, see reference 159.
219) Yasumoto K et al, Cancer Res 45, 1413-7, 1985; Nocardia lung cancer improves prognosis in randomized studies and especially in operable patients.
220) Willox JC et al, Br J Cancer 54: 19-23, 1986, in patients with testicular cancer who will receive cisplatin magnesium randomized study on the formation of kidney damage.
221) Gebbia V et al, Anticancer Res 14: 731-4, 1994, in patients who receive chemotherapy at 50 versus 50 thymopentine reduces the number of fever episodes and leucopenia, but the difference was not significant, nor was the number of fungal infections in thymopentinegroep lower, although there again this difference was not significant, a comprehensive analysis would be interesting.
222) Gochi A et al, Br J Cancer 84: 443-51, OK-432 enhances randomized study in patients operated due to gastric cancer and which are more unfavorable prognostic stand prognosis.
223) Hanaue H et al; Tokai J Exp Clin Med 12: 209-14, 1987, OK-432 improves survival in randomized studies of patients with recurrent gastric cancer, only by intradermal, not by intramuscular injection.
224) Kim SY et al, Cancer 83: 2054-9, 1998, OK-432 intradermal administration, improves as additional adjuvant treatments in addition to FAM and the prognosis of curatively operated gastric cancer patients in principle significant, subgroup analysis showed that this advantage is largely or entirely based on a benefit for patients with stage 3.
225) N Tanaka et al, Cancer 74: 3097-103, 1994; gastric cancer patients received preoperative injection of OK-432 into the tumor, after surgery did the OK-432 group is not demonstrably better, but this was well demonstrated in patients who had stage 3.
226) Ochiai T et al, Cancer Res 43: 3001-7, 1983; Nocardia prolongs the life of patients with stomach cancer is not curative.
227) Braga M et al, Minerva Chir 47: 125-30, 1992; Thymopentine reduces randomized study the risk of sepsis in case of surgery for cancer, on closer analysis, the advantage of thymopentine (almost) entirely to the elderly to to come.
228) Gochi A et al, Nippon Geka Gakkai Zasshi 90: 1439-1442, 1989, in a randomized trial in a small 400 pati137nten surgery because of gastric cancer improves the prognosis of OK-432, was explicit that again for patients with a less favorable prognosis.
229) Nio Y, Tobe T, Nippon Geka Gakkai Zasshi 90: 1436-8, 1989, in patients operated due to gastric cancer was OK-432 partial life expectancy for stage 1 is not, but for stage 2 and 3 to improve.
230) R Tamada et al, Gan To Kagaku Ryoho 14: 716-22, 1987; PSK improves a large-scale randomized study the prognosis of operated gastric cancer patients.
231) Yamamura Y et al; Gan To Kagaku Ryoho 10: 1603-9, 1983, OK-432 improves survival in randomized studies of patients operated on stomach cancer patients.
232) Yamamura Y et al; Gan To Kagaku Ryoho 12: 541-8, 1985, OK-432 prolongs life in randomized studies of incurable stomach cancer patients significantly.
233) Yamamura Y et al; Gan To Kagaku Ryoho 13: 2134-40, 1986; In this randomized study shows the forecast of OK-432 operated gastric cancer patients.
234) K. Fujita, Cancer 59: 2027-30, 1987, OK-432 injected into bladder tumors preoperatively decreases according to randomized study the risk of recurrence significantly.
235) Kyoto Research Group for Digestive Organ Surgery, Ann Surg 216:44-54, 1992, OK-432 improves randomized / double-blind study in over 1000 patients operated due to gastric cancer prognosis significantly.
236 and 237) Kim JP et al, Ann Surgery 216-78, 1992, OK-432 improved the prognosis of gastric cancer patients operated in two separate randomized trials.
238) Osawa S et al; Gan To Kagaku Ryoho 23: 327-31, 1996, OK-432 improved the survival of gastric cancer patients randomized as not significant, the more aggressive forms of gastric cancer, the difference is significant in favor of OK-432.
239) Sugimachi K et al, Cancer Chemother Pharmacol 33: 366-70, 1994, in patients with gastric cancer and peritoneal metastasis appears OK-432 at least in this relatively small randomized study demonstrated no improvement in life expectancy.
Despite this less favorable research it is not surprising that a meta-analysis concerning OK-432 as an agent in gastric cancer went out very positive, see page 405 ff Sakamoto J Immunother
240) Ochiai T, Sato H, Gan To Kagaku Ryoho 10: 373-9, 1983; Nocardia as an additional adjuvant improves survival in curatively operated gastric cancer patients in principle.
241) Saijo N et al; Gan To Kagaku Ryoho 10: 290-5, 1983; Nocardia in a small randomized trial increases the probability regression of pleural effusion in conditions of chemotherapy in lung cancer patients.
242) Ogura T, Gan To Kagaku Ryoho 10: 366-72, 1983; Nocardia improved survival of lung cancer patients in this randomized study is not significant, although this was the case in patients with small cell lung cancer. The overall result was not significant, in all other studies with Nocardia as a therapeutic for lung cancer (84,94,158,209,219 and 241) was always a way, a combined analysis of reference 242 and the aforementioned brackets is very clearly in favor of from Nocardia.
243) Snyderman CH et al, Laryngoscope 109: 915-21, 1999; Additional supplementation in addition to standard power loss in a randomized double-blind study in cancer patients who underwent surgery the risk of infection and hospitalization.
244) Andersson G et al, Gerodontology 12: 12-7, 1995, an extract of linseed reduces the symptoms of dry mouth associated with radiotherapy in head / neck area significantly compared with a methyl cellulose preparation.
245) epistemology AS et al, Ann Surg 223: 316-33, 1996, Supplementation with omega-3 fatty acids from fish oil decreased in a randomized trial in patients with cancer because of the higher parts of the intestinal tract were operated, the number of complications and infections significantly.
246) Motzer RJ et al, J Clin Oncol 18: 2972-80, 2000, 13-cis-retinoic acid increases in patients with advanced kidney cancer, the response probability of interferon improves progression-free phase, the survival time by 13-cis- retinoic acid only non-significantly better.
247) Matthay KK et al, N Engl J Med 14: 341: 1165-1173, 1999; Neuroblastoma patients with poor prognosis (260 in total, after chemotherapy and bone marrow transplant or not 6 months 13-cis-retinoic acid, which resulted in a better disease-free survival at 3 years for the 13-cisretinoinezuurgroep (46% versus 29% in the control group).
248) JA Kohler et al, Br J Cancer 83: 1124-7, 2000, in a randomized trial in neuroblastoma patients showed 13-cis retinoic acid-disease-free survival is not demonstrably improve summation of this study and previous shows still better disease free survival. Short, 13-cis-retinoic acid in these patients is recommended.
249) Luh KT et ak, Cancer 69 :674-9, 1992; Pleural effusion in lung cancer patients with OK-432 more contested than with bleomycin and the effusion-free period with OK-432 also significantly longer.
250) Ferrari AC et al, J Clin Oncol 20: 538-44, 2002, 13-cis-retinoic acid in 30 prostate cancer patients receiving hormonal therapy were randomized based testing, with 13-cis-retinoic acid, 7 patients undetectable PSA levels , without this extra material there were only three, the difference is not significant, further research is needed with larger numbers.
251 and 252) K. Okamura et al, Biomed Pharmacother 43: 177-81, 1989; In two randomized studies, OK-432 as an adjunct to cervical cancer patients disease-free survival and survival improvement seconds.
253) K. Noda et al, Gynecol Oncol 35: 367-72, 1989; In this study proved the OK-432 as an adjunct to cervical cancer patients disease-free survival and survival improvement seconds.
254) Tsujihashi H et al, Hinyokika Kiyo 34: 2111-4, 1988, in a randomized study shows OK-432 to the recurrence of bladder cancer significantly reduced, see references 234 and 255.
255) Nishio S et al, Hinyokika Kiyo 34: 2053-7, 1988; In bladder cancer patients, OK-432 or chemotherapy as treatment given, the risk of recurrence was similar (which has an effect of OK-432 shows), but was agressiviteitsgraad the recurrences in the OK-432 group was significantly lower.
256) Cervical Cancer Immunotherapy Study Group, Cancer 60: 2394-402, 1987, OK-432 as adjuvants enhances the 3-year survival of patients treated for cervical cancer.
257) Kikkawa F et al, Eur J Cancer 29A: 1542-6, 1993, in a stage cervical cancer using OK-432 is not demonstrably better disease-free survival at 5 years, or in two stages and especially if there were no lymph node metastases, in Stage 1 is the better forecast a statistically significant effect arguably more difficult, hence the insignificant results in this subgroup. The combined result of the credentials 251 t / m 256 (minus 254 and 255)) for OK-432 as an adjuvant in the treatment of cervical cancer is obviously very positive.
258) Watanabe Y, Iwa T, J Biol Response Mod 6: 169-80, 1987, OK-432 improves survival in this randomized study of patients with non-small cell lung cancer operable or not.
259) Watanabe Y et al, Nippon Geka Gakkai Zasshi 90: 1432-5, 1989; In this study OK-432 improved survival in patients with non-small cell lung cancer, surgery or not.
260) A Urata et al, Gan To Kagaku Ryoho 10: 1497-503, 1983, OK-432 prolongs chemo in lung cancer patients with pleural effusion (intrapleural administered all) the extra life in case of stage 3 but not in case of stage 4.
261) Nio Y et al, Br J Cancer 80: 775-85, 1999, OK-432 increases in cases of pleural effusion in lung cancer, the survival significantly.
262) Fukushima M et al; Gan To Kagaku Ryoho 23: 303-9, 1996, in a small randomized study found OK-432 as an additional adjuvant survival of operated lung cancer patients do not improve.
263) Lee YC et al, Cancer Immunol Immunother 39: 269-74, 1994; In this small randomized study showed there with OK-432 lung cancer patients operated on for no benefit to be achieved, 208,258 and 259 are for OK-432 as an adjuvant for operated logkankerpatiënten favorably, 262 and 263 are not detectable in the same situation favorable for the OK-432 patients: a meta-analysis of Sakamoto J et al, J Immunother 24: 250-6, 2001, over 11 randomized trials! belongs in favor of OK-432 as an additional adjuvant for operated lung cancer patients.
264) Yajin K et al; Gan To Kagaku Ryoho 15: 1921-7, 1988, OK-432 improves disease-free survival in strottehoofdkanker, with pharyngeal cancers, there was however no detectable effect of OK-432.
265) Kimura T et al, Acta Otolaryngol Suppl 525: 135-41, 1996, OK-432 shows a clear trend in larynxtumoren see fewer relapses compared with no OK-432.
266) Fujimoto S et al, Jpn J Surg 14: 286-92, 1984, SPG improves survival in operated gastric cancer patients as not significant in stage 3, all the result is not significant, combining this research with the numbers 117, 184 and 196 to provide a preliminary analysis, all significant advantage for the SPG.
267) Kucera H, Mischke M, Fortschr Med 100: 760-3, 1982, Vitamin A palmitate was used as an adjunct in advanced cervical cancer to radiation testing, the PHA test (a measure of T-cell activity) was in the vitamin A- group demonstrated better, there was more after 12 months in the vitamin A group, also there is less disease progression, although this latter difference was not significant, it is clear that this small study with larger numbers should be repeated.
268) Yasumoto K et al, Nippon Geka Gakkai Zasshi 84: 321-7, 1983; Nocardia improves remission duration in operable and inoperable lung cancer patients, survival was, however, s is in operable lung cancer in inoperable patients, but not proven.
269) Brackowski R et al, J Biol Regul Homeost Agents 8: 77-80, 1994, Melatonin reduces asthenia, and low blood pressure as side effects of TNF.
270) G Francini et al, Gastroenterology 106: 899-906, 1994, in addition to 5-FU leucovorin improves the chances of curing patients with stage C colon cancer (one in many other studies found fact), not stage the event B.
271) P Duan and HM Wang, Zhongguo Zhong Xi Yi Jie He Za Zhi 22: 515-7, 2002; Astragalus reduces the side effects of chemotherapy and prolongs the period of non-progressive cancer.
272) Wattel E et al, Adv Exp Med Biol 457: 35-46, 1999, Quinine improves survival of patients with P-glycoprotein-positive myelodysplastic syndrome, which receive chemotherapy.
273) Isenberg J et al, Anticancer Res 14: 1399-404, 1994, Propionibacterium granulosum in surgery for colon cancer reduces the number of infections and improves the survival stage 1 and 2, but not in stage 3 or 4. An analysis with a chi-square of all stages together would make sense, however, see also 275.
274) Roszkowski K et al, J Cancer Res Clin Oncol 109: 72-109, 1985, Propionibacterium granulosum in small cell lung cancer improves the duration of remission by chemotherapy and reduces myelosuppression by chemotherapy and the number of infections related to it.
275) Grundmann R et al, Surgery 59: 272-8, 1988; Propionibacterium granulosum reduced in patients who undergo surgery because of colon cancer the number of infections and related it to some new operations, the risk of recurrence and survival in this study were by bacteria not affected. Propionibacterium granulosum comes off so well, in addition to this publication see also 213, 273 and 274.
276) Peters KM et al, Onkologie 13 :124-7, 1990, Propionibacterium avidum appears at least in this small study in surgery for gastric cancer to have no influence on the risk of complications, and there was no effect on disease-free survival and survival sec.
277) K. Mori et al; Gan To Kagaku Ryoho 25: 1159-63, 1998, Kampo, a Japanese herb reduces randomized study the severity of diarrhea in the use of irinotecan.
278) Suzuki S et al; Gan To Kagaku Ryoho 17: 1195-200, 1990; The alkaloid cepharantine reduces leukopenia in breast cancer patients who receive chemotherapy.
279) Saito R et al, Nippon Gan Chiryo Gakkai Shi 24, 2587-93, 1989; Cepharantine leukopenia reduces randomized study in patients with non-small-cell lung cancer.
280) TM Loffler et al, Dtsch Med Wochenschr 117: 1007-1013, 1992; leucovorin improves the chance of regression by 5-FU in patients with metastatic colorectal cancer and extend life.
281) Goseki N et al, Jpn J Cancer Res 86: 484-9, 1995; Methionine Restriction on total parenteral nutrition promotes regression in randomized studies of gastric cancer by 5-FU significantly.
282) Goseki N et al; Gan To Kagaku Ryoho 22: 1028-35, 1995, also in advanced gastric cancer shows total parenteral nutrition with methionine restriction regression of gastric cancer by 5-FU significantly promote.
283) Kitamura S et al; Gan To Kagaku Ryoho 22: 765-75, 1995, Methionine restriction increases the likelihood of response to 5-FU in gastric cancer significantly.
284) Kurihara M et al; Gan To Kagaku Ryoho 22: 911-23, 1995, 5-FU plus methionine restriction improves quality of life in metastatic gastric cancer more than 5-FU alone, which, given the greater regression likelihood by methionine restriction is not crazy.
285) Evans, TR et al, Eur J Cancer 31A: 174-8, 1995; Magnesium Supplementation is side (associated with Mg deficiency) due to 5-FU plus cisplatin against.
286) Ohta T, Morita K, Rinsho Hoshasen 35: 471-4, 1990; Cepharantine leukopenia associated with radiation are more resistant than a adrenochroomafgeleide or cysteine.
287) From Bokhorst MA et al, Am J Clin Nutr 73: 323-32, 2001, arginine appears again good for the immune status, in randomized design arginine shows only a nonsignificant trend toward longer lives with them to bring in patients who, because of throat cancer surgery.
288) Liu CL et al, Zhongguo Zhong Xi Yi Jie He Za Zhi 21: 579-81; Chinese herbs plus chemotherapy compared to chemotherapy alone provide patients with a non-kleicellig lung cancer a better quality of life and better survival (after 2 years 52% versus 24%).
289) H. Li et al, Zhongguo Zhong Xi Yi Jie He Za Zhi 20: 580-2, 2000; Chang'ai Kangfu next adjuvantchemo for colorectal cancer improves immunity in very essential points, and promotes faster recovery from chemotherapy.
290) Jiang CM et al, Zhongguo Zhong Xi Yi Jie He Za Zhi 21, 885-7, 2001, in patients with advanced cancer who receive chemotherapy Chinese herbs prove the immune status and quality of life to improve the survival fell This study has nothing to say because the follow-up lasted only 8 weeks.
291) BF Zhu, Zhongguo Zhong Xi Yi Jie He Za Zhi 14: 89-91,68-9, 1994, Chinese herbs to promote healing in randomized studies of gastric ulcers caused by radiation.
292) Ziegler TR et al, An Intern Med 116: 821-8, 1992; glutamine as an adjunct to bone marrow transplant because of a hematological malignancy in this double-blind study reduced the risk of infection and shortened the length of stay in hospital.
293) GM Wang et al, Zhongguo Zhong Xi Yi Jie He Za Zhi 14: 661-3, 1994, Qi and spleen extract were due to stomach cancer surgery in patients in randomized design (total 60 patients) as additional treatments given in addition to standard chemotherapy, and qi spleen extract resulted in fewer side effects from chemotherapy and made possible a better patient. The small group plus short follow-up made similar statements about disease-free survival impossible.
294) Brown SA, et al, Bone Marrow Transplant 22: 281-4, 1998, Glutamine protects randomized study of liver function in bone marrow transplantation.
295) Morais AA et al; RevHosp Clin Fac Med Sao Paulo 50: 276-9, 1995, in randomized studies in patients to operate on esophageal cancer and are in poor nutritional condition showed glutamine recording time in the hospital to shorten and arginine albumin levels in improve.
296) Jackson DV et al, Am J Med 84: 1016-1022, 1988, in randomized studies show glutamine to reduce neurotoxicity of vincristine.
297) S Mercadante et al, J Pain Symptom Manage 21: 369-72, 2001, Caffeine reduces double-blind randomized study in patients with advanced cancer, the adverse effects of morphine on cognition.
298) Schloerb PR and Amare M, J Paré transparent Enteral Nutr 17: 407-13, 1993, Glutamine decreases in case of bone marrow transplantation, the length of stay in hospital, the infection risk was not demonstrably affected, but said nothing because there are only a total of 29 patients were.
299) Schloerb PR and Skikne BS, J Paré transparent Enteral Nutr 23: 117-22, 1999; glutamine decreased in the slightly larger study than last the length of stay in hospital for bone marrow transplantation, neither the risk of infection was not demonstrably affected, we look at all studies of glutamine to date, referring to hospitalization and / or risk of infection was examined.
300) Jebb SA, et al, Br J Cancer 70 :732-5, 1994, glutamine decreased in this randomized study of 28 patients, mucositis by 5-FU and folinic acid undetectable.
More studies, see this link
